poisar

Stock

Rigel Pharmaceuticals, Inc. RIGL

$46.85+0.82%

Overview

RIGL market data

Price History

RIGL price chart · 1M
O
45.69
H
46.98
L
45.66
C
46.85
Vol
3,673.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$45.69
Previous Close
$46.47
Day High
$46.98
Day Low
$45.66
52 Week High
$47.41
52 Week Low
$25.72
7 Day Return
+3.65%
30 Day Return
+22.42%
90 Day Return
+53.56%
1 Year Return
+60.42%
Daily Notional Volume
$172.1K
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
2.42
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$19.48
Diluted earnings per share over the trailing twelve months.
Beta
1.20
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
116.3%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$24.95 – $52.24
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $780.5M · P/B 1.99 · P/S 2.82.

Company News

8 captured
Piper Sandler Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $49Benzinga · Aug 17, 2026, 4:13 PM
HC Wainwright & Co. Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $85Benzinga · Aug 14, 2026, 5:37 PM
Rigel Pharmaceuticals' VEPPANU For Adults With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative, Estrogen Receptor 1-Mutated Advanced Or Metastatic Breast Cancer Now Available Via U.S. PrescriptionBenzinga · Aug 13, 2026, 12:13 PM
8-K filing — RIGEL PHARMACEUTICALS INC (RIGL)SEC EDGAR · Aug 4, 2026, 8:10 PM
Rigel Pharmaceuticals Q2 EPS $0.88 Beats $0.62 Estimate, Sales $78.700M Beat $69.463M EstimateBenzinga · Aug 4, 2026, 8:03 PM
Onco360® Has Been Selected as a National Pharmacy Partner for VEPPANU™ (vepdegestrant)Globenewswire Inc · Jul 29, 2026, 9:31 PM
Rigel Pharmaceuticals Closes Its Licensing Agreement for VEPPANU; The Agreement Is Effective As Of June 11, 2026 And Rigel Has Made The Upfront Payment Of $70.0M To Be Distributed Evenly Between Arvinas And Pfizer, Consistent With The Terms Of The AgreementBenzinga · Jun 16, 2026, 8:10 PM
HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price TargetBenzinga · Jun 2, 2026, 11:02 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock